Please login to the form below

Not currently logged in
Email:
Password:

Cabometyx

This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.

Merck bulks up in cancer with $2.2bn Peloton buy

Merck bulks up in cancer with $2.2bn Peloton buy

with Exelixis/Ipsen’s multikinase inhibitor Cabometyx (cabozantinib).

Latest news

More from news
Approximately 5 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics